Since its founding in 2014, ScreenPoint Medical’s focus has been to translate cutting edge machine learning research into technology accessible by radiologists to improve screening workflow, decision confidence and cancer detection results.
ScreenPoint’s current product, Transpara® leads the market for AI in mammography reading workflow. Transpara is developed and constantly updated by specialists in machine learning, image analysis, and breast imaging.
ScreenPoint’s origins as the brainchild of two quantitative breast imaging analysis researchers - Professor Sir Michael Brady and Professor Nico Karssemeijer - have also led to unmatched analysis and performance benchmarking relative to peers. As of early 2023, Transpara’s capabilities have been the topic of 16 peer-reviewed publications and many conference presentations.
